SEOUL, South Korea and SILVER SPRING, Md., Nov. 10, 2015 (GLOBE NEWSWIRE) -- GeneOne Life Science Inc. (KSE: 011000 ) today announced that it has signed a cooperative research and development agreement with the Walter Reed Army Institute of Research (WRAIR) to advance GLS-5300, GeneOne’s DNA vaccine for MERS (Middle East Respiratory Syndrome). GeneOne is co-developing GLS-5300 with its affiliate Inovio Pharmaceuticals (NASDAQ: INO ).
As part of this agreement, GeneOne and WRAIR will test the GLS-5300 vaccine in a first-in-human phase I clinical study to be executed at the WRAIR’s Clinical Trials Center. WRAIR will be responsible for all relevant MERS vaccine clinical trial procedures and costs at the Walter Reed Army Institute of Research.
Middle East Respiratory Syndrome is caused by a coronavirus that is related to the severe acute respiratory syndrome (SARS) virus that infected more than 8,000 people over 10 years ago, with a 10% death rate. There is no vaccine or licensed therapeutic against MERS, which spreads from human to human. Since 2012, over 1,650 people have had documented MERS infections and almost 600 (40%) have died. Recently, the largest outbreak of this emergent global health concern outside of Saudi Arabia infected 186 people in South Korea with 36 fatalities.
Earlier this year, GLS-5300 induced 100% protection from a live virus challenge in a preclinical animal study. As published in Science Translational Medicine , the vaccine induced robust immune responses capable of preventing the virus from infecting cells in mice, camels and monkeys. In monkeys, all vaccinated animals in the study were protected from symptoms of MERS when challenged with a live MERS virus.
COL Stephen Thomas, an infectious diseases physician and WRAIR’s Deputy Commander of Operations, expressed concern over the recent MERS outbreak in South Korea and the sustained transmission being observed in the Middle East. “It is very important we seize the opportunity to advance promising MERS vaccine candidates into human trials. We want to understand this vaccine’s safety and potential to protect as soon as possible. I believe U.S. military personnel could be at risk in the event of a large scale MERS outbreak. For this reason, I am glad we will collaborate with GeneOne to take the next steps in developing this vaccine candidate,” Thomas said.
Mr. Young K. Park, CEO, GeneOne, said, “We are pleased to collaborate with the world-class clinicians and scientists at Walter Reed Army Institute of Research. Our partnership with WRAIR will be a catalyst to rapidly advance MERS vaccine development. GeneOne is taking a leading role responding to the MERS health crises and stands ready to advance other DNA vaccines for challenging infectious diseases.
About GeneOne Life Science
GeneOne Life Science Inc. is an international DNA vaccine developer and leading contract manufacturer of DNA plasmid-based agents for pre-clinical and clinical trials for global companies and institutions. It researches and develops DNA vaccines to prevent and treat incurable diseases in South Korea and internationally. The company is headquartered in Seoul, South Korea. VGXI, Inc., GeneOne's wholly-owned manufacturing subsidiary located in Texas, is the largest pure-play cGMP DNA plasmid manufacturing facility in the world.
About the Walter Reed Army Institute of Research (WRAIR)
Established in 1893, the WRAIR is the Department of Defense’s largest biomedical research and development laboratory with a global mission to protect U.S. Service Members from naturally occurring infectious diseases. WRAIR has an extensive international research network that includes sites in Africa, Southeast Asia, and Caucasia (Georgia). The Institute is comprised of research centers focusing on infectious diseases and military psychiatry and neuroscience. For more information, visit websites for WRAIR or its Clinical Trials Center .
Media Contacts: Walter Reed Army Institute of Research Dr. Debra Yourick Office: 301-319-9471 Mobile: 301-792-3941 debra.l.yourick.civ@mail.mil GeneOne Life Science Jeffrey C. Richardson 267-440-4211 jeff@richardsonglobalpr.com
